BARDA

Advancing countermeasures against 21st century health threats by bringing together public private partnerships and advancing innovation. Part of HHS/ASPR.

[BARDA @BARDA]

The newly updated Chemical Hazards Emergency Medical Management (CHEMM) is now available! Built for #EMS, hospitals, poison centers, and #PublicHealth professionals, it offers quick guidance for chemical emergency preparedness and response. Check it out: https://t.co/P7r30wCzA2

[BARDA @BARDA]

We’re developing FloPredict, an AI algorithm that analyzes Doppler signals from @Flosonics's FloPatch, an FDA-cleared wearable ultrasound device. It may enable faster identification and triage of patients at risk for complications from internal hemorrhage: https://t.co/JSNBE3IySn

[BARDA @BARDA]

BARDA & VITAL – a BAN Hub – announced 9 Concept Stage winners in the SMART Antiviral Prize Competition and a $50 million addition to this initiative to support development of antiviral drugs to treat multiple Flaviviridae & Togaviridae viruses. 🔗: https://t.co/Sy3dInZMJn

[BARDA @BARDA]

Seeking proposals to ensure the nation is prepared for the next influenza pandemic. These partnerships will support @US_FDA-licensed manufacturing of influenza antigens & adjuvants and ensure vaccine capacity is available when needed. Proposals due 10/30: https://t.co/pXZ6KgDHTc

[BARDA @BARDA]

@Spectral_MDAI This program's success demonstrates the value of collaborative #PublicPrivatePartnerships between the U.S. government and product development partners to bolster national preparedness and response for burn mass casualty incidents. Learn more: https://t.co/28frrdwlu8

[BARDA @BARDA]

The DeepView AI-Burn System from our partner @Spectral_MDAI is the most recent BARDA-supported burn product to receive FDA approval, licensure or clearance. ️This AI-enabled software is used on Spectral AI’s imaging device to assess the size & healing potential of a burn wound.

[BARDA @BARDA]

@Spectral_MDAI In a large-scale burn mass casualty incident, having fast & accurate wound imaging tools is crucial to improving patient outcomes. This De Novo-cleared system has the potential to optimize the use of limited burn care resources and enable timely triage & transfer to burn centers.

[BARDA @BARDA]

Under Project BioShield, we're partnering w/ @VericelCorp to ensure access to FDA-licensed NexoBrid during a disaster. Vericel will manage product storage to guarantee availability & reduce costs, and further develop NexoBrid to treat blast injuries.

https://t.co/02oyMtRkLV

[HHS ASPR @ASPRgov]

Building domestic manufacturing capacity, BARDA and Schott inaugurated a new production line for production of pharmaceutical glass vials at their facility in Lebanon, PA. Thanks to a longstanding partnership between @BARDA and Schott Pharma, the new production lines, once complete, will be used to make up to 140 million additional 2R vials annually and will support rapid scale production and delivery of medical countermeasures during emergencies.

[BARDA @BARDA]

We awarded a Project BioShield contract to @AVITAMedical for RECELL, an FDA-approved autograft-sparing device that uses a small sample of a patient’s own skin to treat full-thickness burns & trauma, enhancing readiness for radiological & nuclear incidents: https://t.co/Axf3WT013h

[BARDA @BARDA]

This #BARDAInnovation Spotlight highlights the Quic Liver + Kidney test being developed by @in_Diagnostics. Their test pairs with a smartphone app to assess organ health at home, enabling decentralized monitoring during both daily care and emergencies. 🔗: https://t.co/6zjGdXsnOh

[BARDA @BARDA]

BARDA awarded a new Project BioShield contract to @ShionogiUS to enhance nat'l preparedness for biothreats and multidrug-resistant infections while expanding manufacturing to domestic facilities to build stronger defenses against future health emergencies: https://t.co/6e3OmWDIZq

[BARDA @BARDA]

@LumosDX @US_FDA This program's success demonstrates the value of collaborative #PublicPrivatePartnerships between the U.S. government and product development partners to combat antimicrobial resistance (#AMR). Learn more: https://t.co/28frrdwlu8

[BARDA @BARDA]

The FebriDx Bacterial/Non-bacterial Assay from @LumosDX is the 110th BARDA-supported product to receive @US_FDA approval, licensure or clearance. The 510(k) clearance & CLIA-waiver expands use of the test in settings like doctor’s offices, pharmacies, etc. ⬇️

[BARDA @BARDA]

@LumosDX @US_FDA This rapid diagnostic can help determine if a patient’s acute respiratory infection is caused by a bacterial infection. It can also help inform treatment decisions and reduce unnecessary antibiotic use, which has the potential to improve #AntibioticStewardship. ⬇️

[BARDA @BARDA]

BARDA's FASTx solicitation is back! We're funding #PlatformTechnologies that leverage #antiviral conjugates to develop therapeutics against filoviruses and other emerging threats. Learn more here: https://t.co/hn6XwKM4So

[BARDA @BARDA]

We're advancing an AI-enabled assay from Ad Astra Diagnostics that produces results from a blood sample in less than 3 minutes. QScout CBC is designed to provide meaningful results to frontline providers in ambulances, urgent care centers, clinics & more: https://t.co/lNek8YvIRH

[BARDA @BARDA]

We’re accepting proposals for a partner to lead the BARDA Accelerator Network Diagnostics and Medical Devices Hub! Submissions are due by 12PM ET on April 20, 2026. Learn more: https://t.co/GWaM8wu5Uv

[HHS ASPR @ASPRgov]

Today, there are no @US_FDA-approved broad-spectrum therapeutics to treat people with dengue, Zika, West Nile, and Chikungunya and other diseases caused by members of these viral families – but we’re working to change that. BARDA and VITAL, a BARDA Accelerator Network Hub, are partnering to offer prizes to the innovators who can develop novel broad-spectrum antiviral drugs that address this gap in the antiviral pipeline. https://t.co/PjBpJJCBuP

[BARDA @BARDA]

Together with @CompMedUCLA, we're furthering development of the SwabSeq Metagenomic Diagnostic Platform, designed to detect viral pathogens. It could serve as a rapid response tool to detect a novel respiratory virus in a #HealthSecurity emergency: https://t.co/Uj6CIko1Ie